Type II Diabetes: The 45+ Market in the United States for Drugs and Diagnostics

CHAPTER ONE: EXECUTIVE SUMMARY

• Background
• Scope and Methodology
• Size and Growth of Market
• Market Trends and Factors

CHAPTER TWO: INTRODUCTION

• Background
• Population Demographics
• Epidemiology and Pathology of Type II Diabetes

CHAPTER THREE: DIABETES MONITORING

• Background
• Glucose Monitoring
• Hemoglobin A1c
• Ketone Monitoring
• Microalbumin Monitoring

CHAPTER FOUR: TYPE II DIABETES THERAPEUTICS

• Current Approaches to Therapy
  • Patient Education
  • Exercise, Diet and Weight Control
  • Oral Hypoglycemic Agents
  • Insulin
• Emerging Therapeutic Approaches
  • Prevention
  • Oral Hypoglycemic Agents
  • Insulin
  • Gene Therapy
  • Aeta Cell Transplants

CHAPTER FIVE: MARKET ANALYSIS

• Market Size and Growth
  • Type II Diabetes Monitoring Markets
  • Insulin Therapy Markets
  • Oral Hypoglycemic Drugs
• Competitive Outlook
  • Type II Diabetes Monitoring Markets
  • Insulin Therapy Markets
  • Oral Hypoglycemic Drug Markets
• Market Trends

CHAPTER SIX: COMPANY PROFILES

• Overview
• Abbott Laboratories
• Alkermes, Inc
• Amylin Pharmaceuticals
• Aventis Pharma U.S. Division of Aventis
• The Bayer Group (USA) Subsidiary of Bayer AG
• Bristol-Myers Squibb1
• Calyx Therapeutics
• GlaxoSmithKline
• Lexicon Genetics Corporation
• Eli Lilly & Co
• Metabolex, Inc
• MitoKor
• Novo Nordisk
• Pfizer, Inc
• Takeda Pharmaceuticals North America
• Telik, Inc

CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS

• First Conclusion
• Second Conclusion
• Third Conclusion
• Fourth Conclusion
• Fifth Conclusion
• Sixth Conclusion
• Seventh Conclusion
• Eighth Conclusion
• Ninth Conclusion
• Tenth Conclusion
• Eleventh Conclusion

APPENDIX: COMPANY DIRECTORY